» Articles » PMID: 35536069

Serum Trimethylamine N-oxide and the Diversity of the Intestinal Microbial Flora in Type 2 Diabetes Complicated by Diabetic Kidney Disease

Overview
Journal Clin Lab
Specialty Pathology
Date 2022 May 10
PMID 35536069
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Trimethylamine N-oxide (TMAO) serves as a metabolite of intestinal bacteria as well as a urotoxin influencing the prognosis of chronic kidney disease (CKD), which has become a research hotspot in the field of kidney disease. This study preliminarily explored the alternations of the microbial flora and serum TMAO in patients with type 2 diabetes mellitus (T2DM) complicated with diabetic kidney disease (DKD).

Methods: Seventeen T2DM patients at the Affiliated Hospital of Zunyi Medical University between September 2018 and February 2019 were included. Among these patients, 8 patients had T2DM complicated with DKD. Eight healthy volunteers constituted the control group. Fresh stool was collected for Illumina sequencing. Based on the sequencing outcomes, the flora diversity and species differences were analyzed. Serum TMAO, cystatin C, urinary albumin/urine creatinine ratios (ACRs), and routine biochemical outcomes were also compared.

Results: The DKD group exhibited a significantly higher TMAO level than the remaining groups. The high-TMAO group had a significantly increased ACR level compared with the low-TMAO group. TMAO positively correlated with the ACR. Compared with the control group, the DKD group exhibited a decreased flora diversity. At the genus level, both the T2DM group and the DKD group showed decreased numbers of Alloprevotella and Megasphaera compared with the control group. The difference in Megasphaera between the DKD group and the control group was significant.

Conclusions: The alternation of the intestinal microbial flora may participate in the development of DKD, and TMAO and chronic inflammation might be important factors for DKD development.

Citing Articles

Kidney tea [ (Blume) Miq.] improves diabetic nephropathy via regulating gut microbiota and ferroptosis.

Zhou Z, Niu H, Bian M, Zhu C Front Pharmacol. 2024; 15:1392123.

PMID: 38962302 PMC: 11220284. DOI: 10.3389/fphar.2024.1392123.


Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.

Wu X, Zhao L, Zhao Y, He X, Zou L, Zhao Y Pharm Biol. 2024; 62(1):423-435.

PMID: 38757785 PMC: 11104709. DOI: 10.1080/13880209.2024.2351946.


Causal relationship between gut microbiota and diabetic nephropathy: a two-sample Mendelian randomization study.

Yan S, Wang H, Feng B, Ye L, Chen A Front Immunol. 2024; 15:1332757.

PMID: 38533501 PMC: 10964483. DOI: 10.3389/fimmu.2024.1332757.


Trimethylamine N-oxide and kidney diseases: what do we know?.

Gungor O, Hasbal N, Alaygut D J Bras Nefrol. 2023; 46(1):85-92.

PMID: 38039494 PMC: 10962421. DOI: 10.1590/2175-8239-JBN-2023-0065en.


The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease.

Ma L, Zhang L, Li J, Zhang X, Xie Y, Li X Mol Med. 2023; 29(1):148.

PMID: 37907885 PMC: 10617243. DOI: 10.1186/s10020-023-00745-z.